EA201792014A1 - Ацетатная соль бупренорфина и способы получения бупренорфина - Google Patents

Ацетатная соль бупренорфина и способы получения бупренорфина

Info

Publication number
EA201792014A1
EA201792014A1 EA201792014A EA201792014A EA201792014A1 EA 201792014 A1 EA201792014 A1 EA 201792014A1 EA 201792014 A EA201792014 A EA 201792014A EA 201792014 A EA201792014 A EA 201792014A EA 201792014 A1 EA201792014 A1 EA 201792014A1
Authority
EA
Eurasian Patent Office
Prior art keywords
buprenorphine
obtaining
methods
acetate salt
acetate salts
Prior art date
Application number
EA201792014A
Other languages
English (en)
Inventor
С. Фредерик М. Хантли
Эрик Уэйн Катаисто
Хельге Алфред Райш
Арчана ШАРМА
Джейк Лэрри Стимест
Original Assignee
Родс Текнолоджис
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Родс Текнолоджис filed Critical Родс Текнолоджис
Publication of EA201792014A1 publication Critical patent/EA201792014A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

В настоящем описании предложены ацетатные соли бупренорфина и их ангидраты, сольваты, гидраты и их кристаллические формы, причем указанные ацетатные соли бупренорфина, по существу, не содержат примесей. В настоящем описании дополнительно предложен способ получения ацетатных солей, свободного основания бупренорфина, полученного из ацетатных солей, других солей, полученных из свободного основания, и их фармацевтических композиций, по существу, не содержащих примесей.
EA201792014A 2015-03-10 2016-03-09 Ацетатная соль бупренорфина и способы получения бупренорфина EA201792014A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562131114P 2015-03-10 2015-03-10
PCT/IB2016/051332 WO2016142877A1 (en) 2015-03-10 2016-03-09 Acetate salt of buprenorphine and methods for preparing buprenorphine

Publications (1)

Publication Number Publication Date
EA201792014A1 true EA201792014A1 (ru) 2018-01-31

Family

ID=55524412

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792014A EA201792014A1 (ru) 2015-03-10 2016-03-09 Ацетатная соль бупренорфина и способы получения бупренорфина

Country Status (19)

Country Link
US (6) US10406152B2 (ru)
EP (1) EP3283490A1 (ru)
JP (2) JP6660399B2 (ru)
KR (2) KR20200045010A (ru)
CN (1) CN107660207B (ru)
AR (1) AR103902A1 (ru)
AU (2) AU2016230750B2 (ru)
BR (1) BR112017019357A2 (ru)
CA (2) CA2977732C (ru)
CO (1) CO2017009130A2 (ru)
EA (1) EA201792014A1 (ru)
IL (1) IL254384A0 (ru)
MA (1) MA45902A (ru)
MX (1) MX2017011606A (ru)
NZ (1) NZ735736A (ru)
PH (1) PH12017501641A1 (ru)
SG (1) SG11201707350TA (ru)
TW (2) TW202037597A (ru)
WO (1) WO2016142877A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2905112A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Benzylisoquinoline alkaloids (bia) producing microbes, and methods of making and using the same
CA2965469A1 (en) 2013-11-04 2015-05-07 The Board Of Trustees Of The Leland Stanford Junior University Benzylisoquinoline alkaloid (bia) precursor producing microbes, and methods of making and using the same
KR20200045010A (ko) 2015-03-10 2020-04-29 로드스 테크놀로지즈 부프레노르핀의 아세테이트 염 및 부프레노르핀의 제조 방법
EP3292203A4 (en) 2015-05-04 2019-10-09 The Board of Trustees of the Leland Stanford Junior University BENZYL ISOCHINOLIN ALKALOID (BIA) Precursor Producing Microbicides and Method for the Preparation and Use Thereof
JP7266966B2 (ja) 2015-05-08 2023-05-01 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー エピメラーゼ及びベンジルイソキノリンアルカロイドを産生する方法
WO2018075670A1 (en) 2016-10-18 2018-04-26 Antheia, Inc. Methods of producing nor-opioid and nal-opioid benzylisoquinoline alkaloids
GB2579940B (en) 2017-08-03 2022-11-30 Antheia Inc Engineered benzylisoquinoline alkaloid epimerases and methods of producing benzylisoquinoline alkaloids
NZ766474A (en) * 2018-05-11 2023-03-31 Alar Pharmaceuticals Inc Long-acting injectable formulations and crystalline forms of buprenorphine derivatives
WO2023246865A1 (en) * 2022-06-24 2023-12-28 Alar Pharmaceuticals Inc. Stable pharmaceutical composition of buprenorphine and preparation method and use thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3275638A (en) * 1966-09-27 Chjcoo-
US2191786A (en) 1938-03-18 1940-02-27 C A Miketta Continuous process for making adipic acid
BE466549A (ru) 1945-07-17
US3355486A (en) 1965-01-08 1967-11-28 Fmc Corp Continuous process of synthesizing amino-iminomethane-sulfinic acid
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
GB1312447A (en) 1969-05-14 1973-04-04 Nat Res Dev Method of continuous addition of a component to a chemical or biological system and apparatus therefor
US4217287A (en) 1971-10-06 1980-08-12 Gulf Research & Development Company Epoxidation of alpha-olefins
US3936462A (en) * 1972-05-26 1976-02-03 Sterling Drug Inc. 1,2,3,4,5,6-Hexahydro-1-oxo or hydroxy-3-acyl-2,6-methano-3-benzazocines and corresponding 1-esters thereof
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
GB1520139A (en) 1976-06-08 1978-08-02 Ferranti Ltd Gyroscopic apparatus
US4362870A (en) * 1980-01-16 1982-12-07 Regents Of The University Of Minnesota Selective opioid receptor alkylating agents
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4830028A (en) 1987-02-10 1989-05-16 R. J. Reynolds Tobacco Company Salts provided from nicotine and organic acid as cigarette additives
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
CA2002299A1 (en) * 1988-11-10 1990-05-10 Eugene G. Drust Compositions for the transdermal delivery of buprenorphine salts
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE4446600A1 (de) 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US6344211B1 (en) 1994-12-24 2002-02-05 Lts Lohmann Therapie-Systeme Gmbh Transdermal absorption of active substances from subcooled melts
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
TW452907B (en) 1999-11-22 2001-09-01 Winbond Electronics Corp Testing device and method of positive mobile ion contamination
US6994827B2 (en) 2000-06-03 2006-02-07 Symyx Technologies, Inc. Parallel semicontinuous or continuous reactors
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US7560445B2 (en) 2005-07-06 2009-07-14 Taro Pharmaceuticals North America, Inc. Process for preparing malathion for pharmaceutical use
DE102006054731B4 (de) 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
EP2121699B1 (en) 2006-12-04 2012-09-19 Noramco, Inc. Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
MX2009005679A (es) 2006-12-11 2009-06-08 Alcon Res Ltd Fluoresceina sustancialmente pura.
EP2311498A4 (en) * 2008-08-05 2013-07-24 Medrx Co Ltd EXTERNAL PREPARATION COMPRISING A FATTY ACID SALT OR A BENZOIC ACID SALT OF A PHARMACOLOGICALLY ACTIVE BASIC COMPONENT, AND PROCESS FOR PRODUCTION THEREOF
WO2011005452A1 (en) * 2009-07-09 2011-01-13 Mallinckrodt Inc. Method for the enrichment of buprenorphine using chromatographic techniques
PL2621496T5 (pl) * 2010-09-30 2019-05-31 Astrazeneca Ab Krystaliczny koniugat naloksol-peg
TW201338813A (zh) 2011-12-12 2013-10-01 Lohmann Therapie Syst Lts 經皮遞送系統
EA201491875A1 (ru) 2012-04-17 2015-04-30 Пурдью Фарма Л.П. Системы и способы лечения индуцированного опиоидами побочного фармакодинамического ответа
AU2013205080B2 (en) 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
US9834562B2 (en) * 2012-12-31 2017-12-05 Rhodes Technologies 7 beta-substituted 6a, 14a-ethenomorphinans and 7beta-substituted 6a, 14a-ethanomorphinans
BR112015029920A2 (pt) 2013-06-04 2017-07-25 Lts Lohmann Therapie Systeme Ag sistema de administração transdérmica
CN103408553B (zh) * 2013-08-20 2016-02-03 宜昌人福药业有限责任公司 一种氢吗啡酮酸式盐的精制工艺
US8846923B1 (en) * 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
KR20200045010A (ko) * 2015-03-10 2020-04-29 로드스 테크놀로지즈 부프레노르핀의 아세테이트 염 및 부프레노르핀의 제조 방법

Also Published As

Publication number Publication date
AR103902A1 (es) 2017-06-14
BR112017019357A2 (pt) 2018-06-05
AU2016230750A1 (en) 2017-10-12
US20180235955A1 (en) 2018-08-23
AU2019203308A1 (en) 2019-05-30
WO2016142877A1 (en) 2016-09-15
EP3283490A1 (en) 2018-02-21
NZ735736A (en) 2019-02-22
JP6660399B2 (ja) 2020-03-11
SG11201707350TA (en) 2017-10-30
US10835528B2 (en) 2020-11-17
PH12017501641A1 (en) 2018-02-12
MA45902A (fr) 2019-06-19
IL254384A0 (en) 2017-11-30
MX2017011606A (es) 2017-10-26
TW201639856A (zh) 2016-11-16
CA2977732A1 (en) 2016-09-15
US20180162866A1 (en) 2018-06-14
TW202037597A (zh) 2020-10-16
US9926329B2 (en) 2018-03-27
KR20170137738A (ko) 2017-12-13
CA2977732C (en) 2021-02-23
AU2016230750B2 (en) 2019-05-30
CN107660207A (zh) 2018-02-02
US20190314364A1 (en) 2019-10-17
US10874662B2 (en) 2020-12-29
US10406152B2 (en) 2019-09-10
CN107660207B (zh) 2020-09-29
CO2017009130A2 (es) 2017-11-21
US20190298713A1 (en) 2019-10-03
JP2018507882A (ja) 2018-03-22
KR20200045010A (ko) 2020-04-29
TWI699367B (zh) 2020-07-21
US10278967B2 (en) 2019-05-07
CA3104099A1 (en) 2016-09-15
JP2020033359A (ja) 2020-03-05
US20210046066A1 (en) 2021-02-18
US20170197975A1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
EA201792014A1 (ru) Ацетатная соль бупренорфина и способы получения бупренорфина
EA201990565A1 (ru) Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид
MX2018010427A (es) Formas solidas de un inhibidor de tienopirimidindiona acetil coa carboxilasa y metodos para su produccion.
MX2017008136A (es) Sal de l-tartrato de pridopidina.
EA201792503A1 (ru) Соль (s)-kck s-кетамина, соль (r)-kck s-кетамина и способы получения s-кетамина
MX2017002295A (es) Composiciones que comprenden una caseína y métodos para producir las mismas.
EA201692269A1 (ru) Новые композиции, их использование и способы получения
IN2014CH00247A (ru)
EA201790290A1 (ru) Формерные соли (2s,3s)-метил 7-фтор-2-(4-фторфенил)-3-(1-метил-1h-1,2,4-триазол-5-ил)-4-оксо-1,2,3,4-тетрагидрохинолин-5-карбоксилата и способы их получения
PH12017500833A1 (en) Synthesis of copanlisib and its dihydrochloride salt
MX2021010078A (es) Sintesis comercialmente viable de cantaridina y derivados bioactivos de cantaridina.
EA201791466A1 (ru) Способы получения соединений бензохинолина
EA201891342A1 (ru) Изоиндольные соединения
GEP20196974B (en) A novel crystalline form of a benzimidazole derivative and a preparation method thereof
JO3487B1 (ar) تخليق كوبانليسيب وملح الدايهيدروكلوريد الخاص به
MX2018006680A (es) Composiciones de barreras de luz y artículos que las comprenden.
PH12020550703A1 (en) Sulfonamide compounds and use thereof
EA201692288A1 (ru) Способ получения фосфорсодержащих циангидринов
EA201490578A1 (ru) Полиморфная форма питавастатина кальция
SA518391673B1 (ar) مادة إضافة لمواد بناء مصنوعة من الجبس
EA201790235A1 (ru) СПОСОБ ПОЛУЧЕНИЯ ИНГИБИТОРА цГМФ-ФОСФОДИЭСТЕРАЗЫ И ФАРМАЦЕВТИЧЕСКОГО ПРЕПАРАТА ДЛЯ ПЕРОРАЛЬНОГО ПРИМЕНЕНИЯ, СОДЕРЖАЩЕГО КОПРЕЦИПИТАТЫ ТАДАЛАФИЛА
CL2017000074A1 (es) Antagonistas de reproducción de peces
MX2019003684A (es) Formas cristalinas de un derivado de acido biliar.
EA201692246A1 (ru) Способ получения 2,6-диметилбензохинона
EA201691203A1 (ru) Твёрдые формы тенофовира